{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:48:26Z","timestamp":1777420106686,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biologics are used to treat moderate-to-severe Crohn disease (CD). In Japan, ustekinumab was approved for reimbursement for CD treatment in 2017. However, limited information describes utilization of ustekinumab in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe treatment patterns and clinical outcomes of patients with CD treated with ustekinumab in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort drug utilization study was conducted using the Japan Medical Data Center employment insurance database. Patients with a diagnosis of CD who initiated treatment with ustekinumab ( International Classification of Disease, Tenth Revision [ ICD-10] K50.x) from January 1, 2017, to September 30, 2020, were enrolled. Eligible patients were followed up until disenrollment or study end (September 30, 2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 622 patients with CD initiated ustekinumab during the study period; 45.7% had no prior history of biologic use (bio-naive) and 54.3% had previously received \u22651 biologic (bio-experienced); 82.8% of patients received an induction dose of whom 97.5% received a dose within the recommended range (260-520 mg) and 90.8% of patients received their first maintenance dose within a 42- to 70-day interval. Median treatment duration was 14.8 months and 90.2% remained on ustekinumab at study end. Compared with the 12-month period prior to ustekinumab initiation, surgical procedures decreased by 88.0%, gastrointestinal complications by 64.6%, enteral nutrition requirements by 41.9%, and CD-related hospitalizations by 62.6% within 12 months after commencing ustekinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These first real-world data from Japan, where ustekinumab has been used longest for CD treatment, shows that a majority of patients initiated ustekinumab as per the recommended label. Indirect evidence of clinical impact could be relevant in other settings in Asia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221139245","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:36:29Z","timestamp":1672896989000},"page":"1053-1061","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan"],"prefix":"10.1177","volume":"57","author":[{"given":"Yanfang","family":"Liu","sequence":"first","affiliation":[{"name":"Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-0582","authenticated-orcid":false,"given":"Choo Hua","family":"Goh","sequence":"additional","affiliation":[{"name":"Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[{"name":"Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Taipei City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsingwen","family":"Chung","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Officer, Johnson & Johnson, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Regional Medical Affairs, Janssen Asia Pacific, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"bibr1-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2017.07.001"},{"key":"bibr2-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.055"},{"key":"bibr3-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01784-1"},{"key":"bibr4-10600280221139245","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00033"},{"key":"bibr5-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0057-3"},{"key":"bibr6-10600280221139245","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2016.14.2.111"},{"key":"bibr7-10600280221139245","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.16.2.168"},{"key":"bibr8-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"bibr9-10600280221139245","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2019.00026"},{"key":"bibr10-10600280221139245","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2017.15.4.475"},{"key":"bibr11-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0765-6"},{"key":"bibr12-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.367"},{"key":"bibr13-10600280221139245","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz198"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221139245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221139245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221139245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:56Z","timestamp":1777374776000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221139245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10600280221139245"],"URL":"https:\/\/doi.org\/10.1177\/10600280221139245","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}